Sanofi - bullish continuation confirmed on 4HSanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Shown here is the daily chart, with monthly zones/lines of support (green dashed lines) and resistance (red dashed lines). Also shown is a Fibonacci drawn on the monthly chart. In the 4H, Sanofi is clearly bullish ( recent breakout of green Heikin Ashi candles, price above the 50 and 200 MA, recent cross over of 50/200 MA on 4H, and an RSI > 50. Price recently dipped a bit to the downside, but recovered, and is in the 23.8% Fibonacci zone, to which it has returned. On the daily chart, price is between the 50-day MA and 200-day MA, which appears to be crossing over soon. This would be a bullish signal on Daily chart if it happens. If price does move upward, the there are several levels of resistance (monthly), namely at around 83.57, 86.33, 92.94. 95.86 and the all time high of 101.06. A price drop down to 79.00/80.00 would invalidate the bullish signal. Keen to know what others think. Please leave a comment or link to your own ideas! Charts are for information purposes only. Not trade suggestions. DYOR (Do your own research) - act responsibly with your money.
Sanofi
MRNA- Leader in the vaccine race. Ladder buy to avoid the riskModerna is the first company to start the phase 3 trial in July and could have the supply ready earliest by Oct and accelerated approval earliest by December, according to Nami Sumida/BioPharma Dive and morningstar.
Other competitors are scheduled to have accelerated approval the earliest around early 2021.
Sanofi, leading in the fight for COVID-19Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020. If data are positive, regulatory approval could be achieved by the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall.
Sanofi and GSK are committed to making the vaccine available globally
As we are hitting the golden zone in FIB retrace. Im going to put this on watch.
CLOSE TO PULLBACK UP ZONES SANOFI - SAN - 240MNThe price has been ranging widely, coming back to its pre-pandemic trend.
The price is coming very closely to two different important "pullback up" line.
Probability of nice entry for a long direction trade.
In the flip side, if it breaks down those two lines further, there is a risk to see the price approaching the horizontal black line.
For the moment, the probability stays in the direction of the pitchfork, up trending.
SANOFI is likely to go bullish .NASDAQ:SNY is showing signs that it is heading up to around the 54.5 area .There is a possibility that It could return back to around the 48 area and then bounce back from there to around the 54.5 area but I think price would rather break significantly above the 50 until around the 54-55 area .
Time to go long on PIRS, very long.The has been absolutely no fundamental change to this bio company that has multiple big pharma partners. Yet due to the overall biotech downturn NASDAQ:PIRS was hit pretty hard. This presents a true 10 bagger opportunity , and Im not even remotely stretching the truth. The technicals show you why right now is the PERFECT time to buy. A little due diligence will show you why its a must hold in 2016.
As you will find here --> there is plenty in the pipeline, both propietary and partnered. And when your partners are this strong, its hard to fail.